213 related articles for article (PubMed ID: 32662552)
21. Comparing vasopressin and oxytocin fiber and receptor density patterns in the social behavior neural network: Implications for cross-system signaling.
Smith CJW; DiBenedictis BT; Veenema AH
Front Neuroendocrinol; 2019 Apr; 53():100737. PubMed ID: 30753840
[TBL] [Abstract][Full Text] [Related]
22. Position 4 analogues of [deamino-Cys(1)] arginine vasopressin exhibit striking species differences for human and rat V(2)/V(1b) receptor selectivity.
Guillon G; Pena A; Murat B; Derick S; Trueba M; Ventura MA; Szeto HH; Wo N; Stoev S; Cheng LL; Manning M
J Pept Sci; 2006 Mar; 12(3):190-8. PubMed ID: 16130178
[TBL] [Abstract][Full Text] [Related]
23. Identification of amino acid residues that direct differential ligand selectivity of mammalian and nonmammalian V1a type receptors for arginine vasopressin and vasotocin. Insights into molecular coevolution of V1a type receptors and their ligands.
Acharjee S; Do-Rego JL; Oh DY; Ahn RS; Choe H; Vaudry H; Kim K; Seong JY; Kwon HB
J Biol Chem; 2004 Dec; 279(52):54445-53. PubMed ID: 15475353
[TBL] [Abstract][Full Text] [Related]
24. Characterization and localization of oxytocin receptors in the rat testis.
Bathgate RA; Sernia C
J Endocrinol; 1994 May; 141(2):343-52. PubMed ID: 8046305
[TBL] [Abstract][Full Text] [Related]
25. Arginine-vasopressin and the regulation of aggression in female Syrian hamsters (Mesocricetus auratus).
Gutzler SJ; Karom M; Erwin WD; Albers HE
Eur J Neurosci; 2010 May; 31(9):1655-63. PubMed ID: 20525078
[TBL] [Abstract][Full Text] [Related]
26. Molecular modeling of interactions of the non-peptide antagonist YM087 with the human vasopressin V1a, V2 receptors and with oxytocin receptors.
Giełdoń A; Kaźmierkiewicz R; Slusarz R; Ciarkowski J
J Comput Aided Mol Des; 2001 Dec; 15(12):1085-104. PubMed ID: 12160092
[TBL] [Abstract][Full Text] [Related]
27. Selective and non-selective OT receptor agonists induce different locomotor behaviors in male rats via central OT receptors and peripheral V1a receptors.
Wolfe M; Wisniewska H; Tariga H; Ibanez G; Collins JC; Wisniewski K; Qi S; Srinivasan K; Hargrove D; Lindstrom BF
Neuropeptides; 2018 Aug; 70():64-75. PubMed ID: 29807652
[TBL] [Abstract][Full Text] [Related]
28. Structures of the arginine-vasopressin and oxytocin receptor signaling complexes.
Bous J; Fouillen A; Orcel H; Granier S; Bron P; Mouillac B
Vitam Horm; 2023; 123():67-107. PubMed ID: 37718002
[TBL] [Abstract][Full Text] [Related]
29. Oxytocin inhibits the rat medullary dorsal horn Sp5c/C1 nociceptive transmission through OT but not V
García-Boll E; Martínez-Lorenzana G; Condés-Lara M; González-Hernández A
Neuropharmacology; 2018 Feb; 129():109-117. PubMed ID: 29169960
[TBL] [Abstract][Full Text] [Related]
30. Docking ligands to vasopressin and oxytocin receptors via genetic algorithm.
Politowska E; Drabik P; Kazmierkiewicz R; Ciarkowsk J
J Recept Signal Transduct Res; 2002; 22(1-4):393-409. PubMed ID: 12503629
[TBL] [Abstract][Full Text] [Related]
31. Cross-talk among oxytocin and arginine-vasopressin receptors: Relevance for basic and clinical studies of the brain and periphery.
Song Z; Albers HE
Front Neuroendocrinol; 2018 Oct; 51():14-24. PubMed ID: 29054552
[TBL] [Abstract][Full Text] [Related]
32. Analysis of interactions responsible for vasopressin binding to human neurohypophyseal hormone receptors-molecular dynamics study of the activated receptor-vasopressin-G(alpha) systems.
Slusarz MJ; Giełdoń A; Slusarz R; Ciarkowski J
J Pept Sci; 2006 Mar; 12(3):180-9. PubMed ID: 16114100
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the pharmacologic profiles of arginine vasopressin and oxytocin analogs at marmoset, titi monkey, macaque, and human oxytocin receptors.
Pierce ML; French JA; Murray TF
Biomed Pharmacother; 2020 May; 125():109832. PubMed ID: 32018219
[TBL] [Abstract][Full Text] [Related]
34. Ventral striatopallidal oxytocin and vasopressin V1a receptors in the monogamous prairie vole (Microtus ochrogaster).
Lim MM; Murphy AZ; Young LJ
J Comp Neurol; 2004 Jan; 468(4):555-70. PubMed ID: 14689486
[TBL] [Abstract][Full Text] [Related]
35. Molecular pharmacology of human vasopressin receptors.
Thibonnier M; Conarty DM; Preston JA; Wilkins PL; Berti-Mattera LN; Mattera R
Adv Exp Med Biol; 1998; 449():251-76. PubMed ID: 10026814
[TBL] [Abstract][Full Text] [Related]
36. Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
Pena A; Murat B; Trueba M; Ventura MA; Wo NC; Szeto HH; Cheng LL; Stoev S; Guillon G; Manning M
J Med Chem; 2007 Feb; 50(4):835-47. PubMed ID: 17300166
[TBL] [Abstract][Full Text] [Related]
37. Neuropeptide diversity and the regulation of social behavior in New World primates.
French JA; Taylor JH; Mustoe AC; Cavanaugh J
Front Neuroendocrinol; 2016 Jul; 42():18-39. PubMed ID: 27020799
[TBL] [Abstract][Full Text] [Related]
38. Selective and potent agonists and antagonists for investigating the role of mouse oxytocin receptors.
Busnelli M; Bulgheroni E; Manning M; Kleinau G; Chini B
J Pharmacol Exp Ther; 2013 Aug; 346(2):318-27. PubMed ID: 23723434
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the distribution of oxytocin and vasopressin 1a receptors in rodents reveals conserved and derived patterns of nonapeptide evolution.
Freeman AR; Aulino EA; Caldwell HK; Ophir AG
J Neuroendocrinol; 2020 Apr; 32(4):e12828. PubMed ID: 31925983
[TBL] [Abstract][Full Text] [Related]
40. Central vasopressin and oxytocin receptor distributions in two species of singing mice.
Campbell P; Ophir AG; Phelps SM
J Comp Neurol; 2009 Oct; 516(4):321-33. PubMed ID: 19637308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
